Insulet reports Q2 adjusted EPS $1.17, consensus 92c

Reports Q2 revenue $649.1M, consensus $612.26M. “We delivered robust second quarter results, reflecting our team’s strong performance and the compelling impact and appeal of Omnipod 5 for people living with diabetes,” said Ashley McEvoy, President and CEO. “Engaging with our partners, physicians, investors, and Podders this quarter has demonstrated our opportunity to revolutionize diabetes management and the value of our unique position at the nexus of consumer health, medtech, and health tech. As we scale the Company, I’m confident in our ability to grow and create value for all our stakeholders in the future.”